What to Know About This Fund's $74.8 Million Indivior Sale

Divisadero Street Capital Management sold 2,263,703 Indivior shares in Q1, an estimated $74.76 million transaction, reducing its stake to 521,083 shares and cutting the position value by $84.04 million. The sale appears to be profit-taking after a strong run, while Indivior’s fundamentals remain firm: Q1 revenue rose 19% year over year to $317 million and management raised 2026 guidance to as much as $1.29 billion in revenue and $660 million in adjusted EBITDA. The filing is more relevant for positioning than for changing the company’s operating outlook.

Analysis

This is less a thesis change than a de-risking event after a very large rerating. The key second-order signal is that a sophisticated holder chose to monetize strength while the company was simultaneously reaccelerating fundamentals, which often tells you the marginal buyer is now paying up for a cleaner growth story rather than a distressed turnaround. That makes INDV more sensitive to any disappointment in prescription growth, payer dynamics, or execution on SUBLOCADE than the headline multiple alone suggests.

The real competitive question is whether the growth pool is deep enough to sustain premium sentiment once the easy mix and share gains are harvested. In opioid-use-disorder treatment, the best defense is stickier patient retention and formulary access, but that also means any incremental upside depends heavily on reimbursement stability and adoption beyond the current base. If growth is still being driven primarily by a single franchise, the market can re-rate the stock quickly in both directions on monthly script data.

The contrarian setup is that this could be the classic “good fundamentals, crowded winners, weak incremental upside” phase rather than an imminent top. A fund trimming after a near-tripling year can be a prudent portfolio-construction decision, not an indictment of the business, but it also reduces one source of buy-side support if momentum stalls. Over the next 1-3 months, the stock likely trades more on expectation management than on reported results; over 6-12 months, valuation durability hinges on whether management’s raised guide proves conservative or merely achievable.

Key Decisions for Investors

• Avoid chasing INDV after the latest leg higher; wait for a pullback or a post-print setup where the market is forced to re-test whether 2026 guidance is beatable, not just met.
• If already long INDV, trim 25-50% into strength and retain the core until monthly prescription data or payer commentary confirms the growth inflection is durable.
• Consider a pairs trade: long quality pharma cash-flow names with lower growth expectations, short INDV on a relative multiple basis, if the stock continues to discount flawless execution over the next 1-2 quarters.
• For tactical upside exposure, use call spreads rather than outright stock in INDV; the risk/reward is better if you want exposure to another beat-and-raise without paying for unlimited upside after a ~200% run.